( November 19, 2025, 2:04 PM EST) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel said on Nov. 18 that a generic drug maker “has overcome the doubly high burden of persuading us to overturn a jury verdict of no invalidity” in a dispute over a patent relating to a medication for eyelash growth, reversing a Colorado federal jury’s infringement finding and $39 million in damages....